1. Home
  2. TBPH vs EAF Comparison

TBPH vs EAF Comparison

Compare TBPH & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • EAF
  • Stock Information
  • Founded
  • TBPH 2013
  • EAF 1886
  • Country
  • TBPH United States
  • EAF United States
  • Employees
  • TBPH N/A
  • EAF N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • EAF Industrial Machinery/Components
  • Sector
  • TBPH Health Care
  • EAF Energy
  • Exchange
  • TBPH Nasdaq
  • EAF Nasdaq
  • Market Cap
  • TBPH 485.8M
  • EAF 437.2M
  • IPO Year
  • TBPH N/A
  • EAF 1995
  • Fundamental
  • Price
  • TBPH $9.15
  • EAF $1.76
  • Analyst Decision
  • TBPH Buy
  • EAF Hold
  • Analyst Count
  • TBPH 4
  • EAF 6
  • Target Price
  • TBPH $13.75
  • EAF $1.80
  • AVG Volume (30 Days)
  • TBPH 166.7K
  • EAF 1.8M
  • Earning Date
  • TBPH 02-24-2025
  • EAF 02-07-2025
  • Dividend Yield
  • TBPH N/A
  • EAF N/A
  • EPS Growth
  • TBPH N/A
  • EAF N/A
  • EPS
  • TBPH N/A
  • EAF N/A
  • Revenue
  • TBPH $63,192,000.00
  • EAF $541,710,000.00
  • Revenue This Year
  • TBPH $11.41
  • EAF N/A
  • Revenue Next Year
  • TBPH $37.36
  • EAF $5.07
  • P/E Ratio
  • TBPH N/A
  • EAF N/A
  • Revenue Growth
  • TBPH 15.93
  • EAF N/A
  • 52 Week Low
  • TBPH $7.44
  • EAF $0.52
  • 52 Week High
  • TBPH $10.44
  • EAF $2.53
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 49.84
  • EAF 50.71
  • Support Level
  • TBPH $8.35
  • EAF $1.50
  • Resistance Level
  • TBPH $8.86
  • EAF $1.75
  • Average True Range (ATR)
  • TBPH 0.29
  • EAF 0.13
  • MACD
  • TBPH -0.05
  • EAF 0.02
  • Stochastic Oscillator
  • TBPH 58.39
  • EAF 65.00

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two major product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.

Share on Social Networks: